Tetra Bio Pharma Inc
F:JAM1
Balance Sheet
Balance Sheet Decomposition
Tetra Bio Pharma Inc
Tetra Bio Pharma Inc
Balance Sheet
Tetra Bio Pharma Inc
| Nov-2012 | Nov-2013 | Nov-2014 | Nov-2015 | Nov-2016 | Nov-2017 | Nov-2018 | Nov-2019 | Nov-2020 | Nov-2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
0
|
0
|
0
|
0
|
1
|
2
|
14
|
2
|
3
|
5
|
|
| Cash |
0
|
0
|
0
|
0
|
1
|
2
|
14
|
2
|
3
|
5
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
0
|
1
|
|
| Total Current Assets |
0
|
0
|
0
|
0
|
1
|
2
|
15
|
5
|
4
|
6
|
|
| PP&E Net |
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
9
|
9
|
23
|
23
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
1
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
2
N/A
|
0
-92%
|
0
-47%
|
0
-56%
|
2
+3 875%
|
11
+601%
|
23
+110%
|
29
+22%
|
29
+3%
|
8
-74%
|
|
| Liabilities | |||||||||||
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
3
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
|
| Total Current Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
3
|
4
|
7
|
7
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
0
N/A
|
0
N/A
|
0
+900%
|
0
+170%
|
0
-48%
|
0
N/A
|
3
N/A
|
4
+54%
|
7
+72%
|
7
+8%
|
|
| Equity | |||||||||||
| Common Stock |
5
|
5
|
0
|
1
|
3
|
9
|
35
|
56
|
71
|
92
|
|
| Retained Earnings |
4
|
6
|
0
|
1
|
1
|
0
|
17
|
36
|
53
|
107
|
|
| Additional Paid In Capital |
1
|
1
|
0
|
0
|
0
|
2
|
4
|
4
|
4
|
15
|
|
| Total Equity |
2
N/A
|
0
-93%
|
0
N/A
|
0
-2 200%
|
1
N/A
|
11
+670%
|
21
+87%
|
25
+18%
|
23
-8%
|
0
-99%
|
|
| Total Liabilities & Equity |
2
N/A
|
0
-92%
|
0
-47%
|
0
-56%
|
2
+3 875%
|
11
+601%
|
23
+110%
|
29
+22%
|
29
+3%
|
8
-74%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
26
|
26
|
25
|
58
|
85
|
124
|
163
|
213
|
284
|
402
|
|